Table 2.
Baseline demographic and clinical characteristics of treatment effect cohort (part 1)
| Untreated patients | Treated patients | |
|---|---|---|
| (n = 30) | (n = 30) | |
| Age at surgery (years), mean (range) | 69.6 (44–83) | 64.0 (42–77) |
| Sex ratio (M : F) | 19 : 11 | 14 : 16 |
| Neoadjuvant therapy | ||
| Chemotherapy | ||
| FOLFIRINOX ≥ 4 cycles | – | 11 |
| FOLFIRINOX < 4 cycles* | – | 2 |
| Gemcitabine + other ≥ 4 cycles | – | 5 |
| Gemcitabine + other < 4 cycles | – | 1 |
| Chemoradiotherapy | ||
| Gemcitabine ≥ 2 cycles and RTx × 1† | – | 7 |
| Gemcitabine < 2 cycles and RTx × 1 | – | 1 |
| FOLFIRINOX ≥ 4 cycles and RTx × 1 | – | 1 |
| Capecitabine ≥ 2 cycles RTx × 1 | – | 1 |
| Capecitabine < 2 cycles RTx × 1 | – | 1 |
| Type of surgery | ||
| Pancreatoduodenectomy | 24 | 24 |
| Distal pancreatectomy | 6 | 4 |
| Total pancreatectomy | 0 | 2 |
*
One patient also received one cycle of FLOX (combination treatment consisting of fluorouracil, leucovorin, and oxaliplatin). †One patient received gemcitabine in combination with oxaliplatin. FOLFIRINOX, combination treatment consisting of leucovorin, fluorouracil, irinotecan, and oxaliplatin; RTx, radiotherapy.